Every Form 4 that Aprea Therapeutics, Inc. (APRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APRE filings page.
Aprea Therapeutics, Inc. director Michael Grissinger received equity compensation in the form of restricted stock units and stock options. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, if he continues serving on the board through that date.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036, subject to the same service-based condition. After these grants, he directly holds 6,024 shares of common stock and 12,555 stock options.
Aprea Therapeutics, Inc. director Gabriela Gruia received new equity compensation on June 16, 2026. She was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if she continues serving on the board through that date, with possible acceleration under certain conditions.
She also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027, subject to the same service condition and potential acceleration, and expire on June 16, 2036. Following these grants, she holds 4,180 shares of common stock directly.
Aprea Therapeutics director Richard Peters received equity-based compensation rather than trading shares on the market. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration conditions.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027 under the same service and acceleration conditions and expire on June 16, 2036. Following these awards, he holds 6,254 common shares directly.
Aprea Therapeutics director John B. Henneman III received new equity awards. He was granted 3,135 restricted stock units on June 16, 2026, which will vest and settle in common stock on June 16, 2027, if he remains on the board. He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. Following these awards, he directly holds 13,364 shares of common stock, while the options and restricted stock units represent additional potential future ownership.
Aprea Therapeutics director Jean-Pierre Bizzari received new equity awards. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if he continues serving on the board and certain acceleration conditions do not apply.
He also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under the same service-based conditions. Following the grant, he directly holds 4,180 common shares, and the options expire on June 16, 2036.
Aprea Therapeutics director Marc Duey reported new equity awards rather than market trades. He received 3,135 restricted stock units on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration under certain conditions.
Duey was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, expiring on June 16, 2036. These options vest in full on June 16, 2027, subject to continued board service and similar acceleration terms. After these awards, he directly holds 259,290 common shares. An additional 602 shares are held indirectly by his spouse, and he disclaims beneficial ownership of those securities.
Aprea Therapeutics director Rifat Pamukcu reported new equity awards and updated holdings. On June 16, 2026, he received 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, subject to his continued board service and possible acceleration under certain conditions.
He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under similar service-based conditions. Following these awards, he directly holds 8,581 common shares and 12,555 options, and indirectly holds 14,108 common shares through ZNZ Holdings LLC, where he serves as Manager Partner.
Aprea Therapeutics director Bernd R. Seizinger reported equity awards that increase his stake in the company. He received 3,135 restricted stock units granted on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, as long as he continues serving on the board. He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. After these grants, he directly holds 48,910 common shares.
Aprea Therapeutics SrVP/CFO John P. Hamill bought warrants linked to 61,956 shares of common stock in a private placement. On March 31, 2026, he acquired 30,978 pre-funded warrants at $0.808 per warrant less a $0.001 exercise price and 30,978 accompanying common warrants with a $0.683 exercise price. The warrants are immediately exercisable but subject to a Beneficial Ownership Limitation that prevents exercises above 4.99% ownership of common stock or 9.99% of combined voting power.
Aprea Therapeutics director Richard Peters bought derivative securities linked to the company’s common stock. On March 31, 2026, he acquired pre-funded warrants to purchase 123,915 shares of common stock in a private placement, at a purchase price of $0.808 per pre-funded warrant, less the $0.001 exercise price. He also received accompanying common warrants to purchase up to 123,915 additional shares of common stock, with a $0.683 exercise price per share. Both the pre-funded and common warrants are immediately exercisable, but their exercise is limited by a “Beneficial Ownership Limitation” that generally caps common stock ownership at 4.99% of outstanding shares or 9.99% of aggregate voting power. The common warrants will expire on the earlier of December 31, 2029, or 30 calendar days after exercise of the related pre-funded warrants, proportional to the exercised amount.
Aprea Therapeutics president and CEO Gilad Oren reported new equity awards. He received stock options for 80,700 shares of common stock at an exercise price of $0.765 per share, expiring on March 12, 2036. These options vest 25% on March 12, 2027, with the remainder vesting ratably over the following 36 months, subject to continued employment.
Oren was also granted 20,175 restricted stock units that vest in three equal annual installments beginning on March 12, 2027, also subject to continued employment. Following these grants, he directly holds 393,895 shares of common stock. Additional indirect holdings of 1,200 and 600 shares are reported for his daughter and son, with beneficial ownership disclaimed.
Aprea Therapeutics reported that SrVP/CFO/Principal Financial and Accounting Officer John P. Hamill received new equity compensation. He was granted 40,380 stock options with an exercise price of $0.765 per share, expiring on March 12, 2036.
Twenty-five percent of these options vest on March 12, 2027, with the remainder vesting monthly over the following 36 months, contingent on continued employment. Hamill also received 10,095 restricted stock units, vesting in three equal annual installments starting March 12, 2027. Following the RSU grant, his common stock holdings total 43,528 shares.
Aprea Therapeutics’ President and CEO Gilad Oren, who is also a director, reported buying 28,100 shares of common stock in a private placement that closed on January 30, 2026 at $0.89 per share. After this purchase, he directly holds 373,720 common shares, with additional indirect holdings of 1,200 shares by his daughter and 600 shares by his son.
Oren also received 28,100 common warrants with an exercise price of $0.765 per share, immediately exercisable but subject to limits so his ownership generally cannot exceed 4.99% of outstanding common stock or 9.99% of combined voting power. These warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144 on a cashless basis.
Aprea Therapeutics’ Senior Vice President and CFO John P. Hamill bought 5,700 shares of common stock in a private placement on January 30, 2026 at $0.89 per share, bringing his direct holdings to 33,433 shares.
He also received common warrants to purchase up to 5,700 additional shares at an exercise price of $0.765 per share. The warrants are immediately exercisable but include caps so his and his affiliates’ beneficial ownership cannot exceed 4.99% of common stock or 9.99% of total voting power after exercise. The warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.
Aprea Therapeutics, Inc. reported that a director purchased 21,459 shares of common stock in a private placement on December 10, 2025 at a price of $1.165 per share and received accompanying common warrants to purchase up to 21,459 additional shares at an exercise price of $1.04.
After the transaction, the report shows 256,155 shares held directly, 602 shares held by a spouse and 21,459 common warrants. The warrants are immediately exercisable but cannot be used if exercise would push the holder above 4.99% beneficial ownership of common stock or 9.99% of the issuer’s total voting power, and they expire five years after the earlier of a registration of the underlying shares or the date those shares become eligible for resale under Rule 144 on a cashless basis.
Aprea Therapeutics, Inc. reported an insider purchase by its Senior Vice President, Chief Financial Officer and Principal Financial & Accounting Officer, John Hamill. On December 10, 2025, he acquired 5,000 shares of common stock in a private placement at a purchase price of $1.165 per share, bringing his directly held common stock to 27,733 shares.
As part of the same private placement, he also received common warrants to purchase up to 5,000 additional shares of common stock at an exercise price of $1.04 per share. The warrants are immediately exercisable but contain beneficial ownership limits that generally cap holdings at 4.99% of outstanding common stock or 9.99% of combined voting power. The warrants expire on the fifth anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.
Aprea Therapeutics, Inc. reported that its President and CEO, who also serves as a director, participated in a private placement that closed on December 10, 2025. The executive acquired pre-funded warrants to purchase 21,459 shares of common stock at a purchase price of $1.165 per pre-funded warrant, and received accompanying common warrants to purchase up to an additional 21,459 shares.
The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share, and the common warrants are immediately exercisable at an exercise price of $1.04 per share, in each case subject to a beneficial ownership cap of 4.99% of outstanding common stock or 9.99% of total voting power. Following these transactions, the executive beneficially owns 345,620 common shares directly, plus additional shares held indirectly through a daughter and son, as well as the newly issued pre-funded and common warrants.